Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
Open Access
- 23 February 2021
- journal article
- research article
- Published by Elsevier BV in Neurotherapeutics
- Vol. 18 (2), 1127-1136
- https://doi.org/10.1007/s13311-020-01004-3
Abstract
No abstract availableKeywords
Funding Information
- Cytokinetics Incorporated (N/A)
This publication has 28 references indexed in Scilit:
- Spinal Muscular AtrophyNeurologic Clinics, 2015
- The Small-Molecule Fast Skeletal Troponin Activator, CK-2127107, Improves Exercise Tolerance in a Rat Model of Heart FailureThe Journal of pharmacology and experimental therapeutics, 2015
- Spinal muscular atrophy: Diagnosis and management in a new therapeutic eraMuscle & Nerve, 2014
- Abnormalities in Early Markers of Muscle Involvement Support a Delay in Myogenesis in Spinal Muscular AtrophyJournal of Neuropathology and Experimental Neurology, 2014
- Performance of the timed “up & go” test in spinal muscular atrophyMuscle & Nerve, 2013
- Responsiveness of the Motor Function Measure in Patients With Spinal Muscular AtrophyArchives of Physical Medicine and Rehabilitation, 2013
- Childhood spinal muscular atrophy induces alterations in contractile and regulatory protein isoform expressionsNeuropathology and Applied Neurobiology, 2008
- An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patientsNeuromuscular Disorders, 2007
- A motor function measure scale for neuromuscular diseases. Construction and validation studyNeuromuscular Disorders, 2005
- Natural history of denervation in SMA: Relation to age, SMN2 copy number, and functionAnnals of Neurology, 2005